Skip to content

Author

Zheng-Yu Jiang

We have 3 of 17 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Discovery of Tricyclic Oxazinoquinolinone-Based BCL6 PROTAC Degraders with Potent Activity Against Diffuse Large B-Cell Lymphoma

Overall, compound 15 represents a promising BCL6 PROTAC degrader for DLBCL, which induced rapid and efficient BCL6 degradation in OCI-LY1 cells and displayed potent antiproliferative activity in BCL6-dependent DLBCL cells.

Xue-Tao Chen, Ru-Ju Xu, Xiao-Ran Wang et al. · 0 citations
Open access Sep 2026

Allosteric modulation of YTHDFs by ellagic acid suppresses triple-negative breast cancer via non-canonical activation of the HIF-1α pathway

Summary Triple-negative breast cancer (TNBC) lacks effective targeted therapies, and YTHDF proteins are frequently overexpressed in this malignancy, which correlates with adverse prognosis. Through high-throughput drug screening, we identify ellagic acid (EA) as a compound that binds to YTHDF proteins and disrupts thei...

Jian-Heng Zhou, Yu-Yuan Li, Xue-Tao Chen et al. · 0 citations
Open access Aug 2026

Harnessing the E3 Ligase KLHL12 for Tumor-Selective Protein Degradation.

KLHL12 is identified as a potentially tumor-selective E3 ligase and the development of the first-in-class KLHL12-recruiting PROTACs are reported, which established KLHL12 as a promising tumor‑selective E3 ligase and provided a KLHL12-recruiting PROTAC platform for cancer therapy.

Shicheng Xu, Xian Zhang, Shun-Bo Hu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.